Trial Profile
OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS)(also called velocardiofacial syndrome).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Mar 2019
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 22 Mar 2019 Status changed from recruiting to completed.
- 30 Jun 2012 Eli Lilly added as associations as reported in the European Clinical Trials Database record.
- 21 Apr 2012 Planned end date changed from 3 Nov 2012 to 7 Sep 2013 as reported by European Clinical Trials Database record.